• Explore /
  • Poster
  • / Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study.

Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study.

Abstract Poster

Authors

null

Francesco Passamonti

University of Insubria, Varese, Italy

Francesco Passamonti , Andrea Patriarca , Steven Knapper , Candido Rivera , Joseph Scandura , Timothy Devos , Nikki Granacher , Adam J. Mead , Stephen Oh , Jeanne M. Palmer , Raajit Rampal , Lino Teichmann , Jie Cui , Sandra Klein , Gozde Colak , Claire Harrison

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT02158858

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7019)

DOI

10.1200/JCO.2023.41.16_suppl.7019

Abstract #

7019

Poster Bd #

149

Abstract Disclosures

Similar Posters

First Author: Justin M. Watts

First Author: Arvind Dasari

First Author: Justin M. Watts

First Author: Jiayu Wang